nafcillin

DRUG2 trials

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

OsteomyelitisStaphylococcal Bacteraemia

Phase 2

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

CompletedNCT00428844

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Osteomyelitis

Start: 2007-06-26End: 2010-06-23Updated: 2018-01-31

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

CompletedNCT04775953

National Institute of Allergy and Infectious Diseases (NIAID)Staphylococcal Bacteraemia

Start: 2021-04-22End: 2023-12-01Updated: 2024-12-10

Related Papers

Dalbavancin for Treatment of <i>Staphylococcus aureus</i> Bacteremia

JAMA2025-08-1317 citations

Substance use disorder-associated infections’ treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) – an investigator-initiated single-arm unblinded prospective cohort study

Therapeutic Advances in Infectious Disease2024-01-011 citations

998. Clinical Outcomes and Cost Savings of Dalbavancin Use in OPAT: Focus on Complicated <i>Staphylococcus aureus</i> Infections

Open Forum Infectious Diseases2022-12-011 citations

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Trials2022-05-1650 citations

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.

2021-12-146 citations